Difference between revisions of "Regimen classes"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
Line 39: Line 39:
 
=Taxane-based regimen=
 
=Taxane-based regimen=
 
==Docetaxel-containing regimen==
 
==Docetaxel-containing regimen==
 +
=Temozolomide-based regimen=
  
 
=Tyrosine kinase inhibitor therapy=
 
=Tyrosine kinase inhibitor therapy=

Revision as of 23:42, 21 August 2022

The purpose of this page is to define regimen classes that will be used in the HemOnc ontology; it is not for other purposes at this time.

Alkylator-based regimen

Anthracycline-based regimen

Anti-CD20-based regimen

Rituximab-containing regimen

Anti-HER2-based regimen

Trastuzumab-based regimen

Anti-VEGF biologic therapy

Bevacizumab-containing regimen

Dacarbazine-based regimen

Endocrine-based regimen

Androgen receptor-directed therapy

Antiestrogen therapy

Fludarabine-based regimen

Fluoropyrimidine-based regimen

5-FU-based regimen

Irinotecan-based regimen

Pemetrexed-containing regimen

Platinum-based regimen

Cisplatin-based regimen

Oxaliplatin-based regimen

Platinum-based chemoradiation

Platinum doublet

Single-agent regimen

Single-agent cytotoxic chemotherapy

Single-agent hormonotherapy

Single-agent immunotherapy

Single-agent targeted therapy

Taxane-based regimen

Docetaxel-containing regimen

Temozolomide-based regimen

Tyrosine kinase inhibitor therapy

BRAF TKI therapy

EGFR TKI therapy

VEGFR inhibitor therapy